
FDA Lifts Pause on Chikungunya Vaccine IXCHIQ Use in Adults 60+ Following Safety Review
After a three-month review, the FDA and EMA have cleared continued use of IXCHIQ in adults 60+, adding new safety warnings for elderly individuals with chronic conditions.



























